Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to addressing unmet medical needs through the development of innovative therapies. The company is focused on discovering and developing treatments for diseases with significant demand and lack of solutions, such as Demodex blepharitis, Lyme disease, and rosacea. Tarsus has successfully launched XDEMVY, an FDA-approved treatment for Demodex blepharitis, and is actively advancing its pipeline with investigational therapies like TP-04 for rosacea and TP-05 for Lyme disease prevention. Guided by a commitment to scientific research, patient needs, and a culture of teamwork, Tarsus Pharmaceuticals strives to be a leader in revolutionizing treatment options.